The estimated Net Worth of Gregory J Divis is at least $3.07 Milhão dollars as of 10 August 2023. Mr Divis owns over 10,000 units of Avadel Pharmaceuticals plc stock worth over $2,171,715 and over the last 7 years he sold AVDL stock worth over $0. In addition, he makes $897,000 as CEO & Director at Avadel Pharmaceuticals plc.
Mr has made over 7 trades of the Avadel Pharmaceuticals plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of AVDL stock worth $132,000 on 10 August 2023.
The largest trade he's ever made was buying 50,000 units of Avadel Pharmaceuticals plc stock on 27 May 2022 worth over $102,500. On average, Mr trades about 6,537 units every 108 days since 2017. As of 10 August 2023 he still owns at least 159,100 units of Avadel Pharmaceuticals plc stock.
You can see the complete history of Mr Divis stock trades at the bottom of the page.
Gregory J. Divis Jr. is the CEO & Director at Avadel Pharmaceuticals plc.
As the CEO & Director of Avadel Pharmaceuticals plc, the total compensation of Mr Jr at Avadel Pharmaceuticals plc is $897,000. There are no executives at Avadel Pharmaceuticals plc getting paid more.
Mr Jr is 54, he's been the CEO & Director of Avadel Pharmaceuticals plc since . There are 3 older and 2 younger executives at Avadel Pharmaceuticals plc. The oldest executive at Avadel Pharmaceuticals plc is Gregory J. Davis, 56, who is the VP of Corp. and Bus. Devel..
Gregory's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380.
Over the last 8 years, insiders at Avadel Pharmaceuticals plc have traded over $7,791,038 worth of Avadel Pharmaceuticals plc stock and bought 775,568 units worth $4,366,224 . The most active insiders traders include Healthcare Master Fund Ltd ..., Kevin Broadfin Capital, Llc..., eNaseem Amin. On average, Avadel Pharmaceuticals plc executives and independent directors trade stock every 43 days with the average trade being worth of $381,436. The most recent stock trade was executed by Thomas S Mchugh on 16 January 2024, trading 2,000 units of AVDL stock currently worth $29,000.
avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.
Avadel Pharmaceuticals plc executives and other stock owners filed with the SEC include: